MARKERS FOR FFPE NON-TUMORAL TISSUE Cristina Villena Pulmonary - - PowerPoint PPT Presentation

▶

Aug 15, 2022 26 likes •150 views

OPTIMARK PROJECT: NEW QUALITY MARKERS FOR FFPE NON-TUMORAL TISSUE Cristina Villena Pulmonary Biobank Consortium CIBERES. Scientific coordinator Spanish National Biobank Network ISCIII. Coordinator Spanish National Biobank Network 0001

SLIDE 1

OPTIMARK PROJECT: NEW QUALITY MARKERS FOR FFPE NON-TUMORAL TISSUE

Cristina Villena

Pulmonary Biobank Consortium CIBERES. Scientific coordinator Spanish National Biobank Network – ISCIII. Coordinator

SLIDE 2

Spanish National Biobank Network

0001 CIBERES- H. U. SON ESPASES 0002 IDIS- C.H.U SANTIAGO 0004 CNIO 0006 FJD 0007 NAVARRABIOMED 0008 MD ANDERSON 0010 HOSPITAL RAMON Y CAJAL 0011 IMIM 0013 H12O 0014 F-CIEN 0016 IDIBAPS 0017 FISABIO 0018 CLINICA UNIVERSIDAD DE NAVARRA 0019 IDIVAL 0020 HOSPITAL UNIV. PUERTA DE HIERRO 0021 BIOBANCO VASCO 0023 ISPA 0024 IDIBELL 0025 IDIPAZ 0027 IRBLleida 0029 INSTITUTO INV. S. PERE VIRGILI 0032 INSTITUTO INV. BIOMED. LA CORUÑA (INIBIC) 0033 INSTITUTO INV. BIOMED. GIRONA DR.JOSEP TRUETA 0034 INSTITUTO INV. SANITARIA GALICIA SUR 0036 HOSPITAL SANT JOAN DE DEU 0037 H. U. FUNDACION ALCORCON 0038 IMIB 0039 INSTITUTO ARAGONES CIENCIAS SALUD 0040 INSTITUTO INV. SANIT. H. CLINICO SAN CARLOS 0041 BBSPA 0042 INSTITUTO INV. SANITARIA GREGORIO MARAÑON (IiSGM) 0043 H LA FE 0044 U Salamanca 0045 HUGTiP 0047 VHIR 0049 INCLIVA 0050 HOSPITAL DE LA PRINCESA 0051 FIVO XXXX ISCIII -BioNER

SLIDE 3

Biospecimens and Personalized Medicine

Personalized medicine (PM) using biomarkers in screening, diagnosis, treatment, and monitoring of cancer will depend on accurate, reproducible data derived from patient samples in the clinical setting. Biobanks need:

To know the effect of pre-analytical variables on biospecimens (quality

and integrity).

To determine the potential applications into research of biospecimens

stored in biobanks and Pathology Services. PM is limited to pre-analytical factors, compromising sample stability, molecular integrity, quality and… BIOMARKER DISCOVERY.

SLIDE 4

OPTIMARK project

1. Identify the pre-analytical variables more relevant in tissues, which could

affect the clinical biomarkers development.

2. Develop and validate a common procedure to clarify the potential use of

the samples in research, especially those without pre-analytical control.

3. To allow collections to be available to the scientific and biotechnological

community, with a very good control of their pre-analytical variables, so that they can evaluate the sensitivity of their developing biomarkers to these factors.

OBJECTIVES

SLIDE 5

374 patients (30-65 y.o.; in brain up to 75 y.o. without vascular pathology)
Healthy tissue (non-tumor)
Pre-analytical factor: storage time

Methods

Checking non other relevant pathologies in the organ selected.

If we are able to find a sensitivity biomarker with the sample age, probably we could use it to evaluate the impact of other pre-analytical factors.

Control: extraction time <1 year A: extraction time between 1 to 5 years B: extraction time between 5 to 10 years C: extraction time between 10 to 20 years D: extraction time >20 years Tissue Brain Breast Colon Endomet. Lung Stomach n 47 67 75 26 46 17

SLIDE 6

1st Antigenicity igenicity analysi ysis

(Aperio Versa 200)

Ki67 Vimentin CD31 Lung Breast Stomach Brain Colon Endomet

Validation

f results

Lung Brain Statistical analysis and new biomarker testing

Experimental design

2nd Antig igeni enicity ity analysi ysis

(Aperio Versa 200)

TTF-1 SDHB B-catenin BCL2 cFOS

SLIDE 7